Alpha-Gal Content for Select Medications Per Manufacturer

Total Page:16

File Type:pdf, Size:1020Kb

Alpha-Gal Content for Select Medications Per Manufacturer Alpha-gal Content for Select Medications Per Manufacturer Updated January 2019 Galactose-alpha-1,3-galactose (Alpha-Gal), is a delayed allergy to mammal meat (e.g., beef, pork). This allergy is caused by a lone star tick bite. Many animal by-products may contain the alpha-gal epitope. Patients with this allergy should avoid any medications, supplements, or foods that may contain alpha-gal. Certain inactive ingredients in medications, such as gelatin, glycerin, glycerol, lactic acid, stearic acid, and magnesium stearate; may be animal derived. A *Disclaimer: Information is subject to change based on lot number of medication. There may also be comprehensive list of medications containing alpha-gal or animal by-products is unavailable at this time. The list cases where risk vs benefit needs to be assessed in deciding whether to use alpha gal medications. below outlines select medications that DUH Pharmacy has contacted the manufacturers for to determine alpha-gal Please contact Pharmacy for review of medications prior to ordering and/or to determine if there are content. potential alternatives that should be considered as part of this assessment. Drug Name Manufacturer OK to Use? Notes Acetaminophen 325 mg tablet McNeill, McKesson No Contains magnesium stearate and gelatin Acetaminophen 325 mg tablet Major Yes Acetaminophen 10 mg/mL injection Mallinckrodt Yes Acetaminophen 160 mg/5 mL liquid Pharmaceutical Associates No Contains glycerin Acetaminophen suppository G&W, Perrigo No Acetaminophen-butalbital-caffeine (Fiorcet) tablet American Health No Acetaminophen-codeine 300mg-30mg tablet Mallinckrodt No Acetaminophen-codeine 120mg-12mg elixir Pharmaceutical Associates No Contains glycerin Adult cardioplegia (induction) DCF Yes Adult cardioplegia (maintenance) DCF Yes Albumin 5% and 25% Grifols Yes Contains no animal or mammalian by-products Alprazolam tablet (all strengths) Major, Mylan, Mckesson No Alvimopan 12 mg capsule Cubist No Contains gelatin (bovine and porcine) Aminocaproic acid 500 mg tablet Hospira No Contains magnesium stearate and stearic acid Aminocaproic acid 250 mg/mL injection Yes Amiodarone 50 mg/mL injection Baxter Yes Amlodipine 5 mg tablet AvKARE Yes Amlodipine 5 mg tablet Major Yes Ampicillin injection Fresenius Kabi Yes No animal byproducts or gluten. No final product testing for either. Aprepitant 40 mg capsule Merck, Sandoz No Contains gelatin (bovine and porcine) Aspirin 81 mg chewable tablet Hospak Yes Aspirin 81 mg EC tablet GeriCare No Aspirin 325 mg EC tablet McKesson No Contains anhydrous lactose (Phone: 855-625-4677) Atorvastatin 40 mg tablet Major, Mylan Yes Bacitracin 50,000 unit injection X-Gen No May contain milk and milk-derivatives (bovine) Bacitracin 50,000 unit injection Fresenius Yes No animal byproducts or gluten. No final product testing for either. Baclofen 10 mg tablet McKesson & American Health No Contains magnesium stearate Belladonna-opium suppository Perrigo Yes No addition of animal by-products, but no final confirmatory testing Balanced Salt Solution (BSS) 15ml Alcon Yes Beclomethasone (QVAR) 80 mcg inhaler Teva Yes BSS Bag 500ml Alcon Yes BSS Plus Bottle 500ml Alcon Yes Bisacodyl 10 mg suppository G&W Yes Bisacodyl 5 mg tablet Major, Rugby No Bivalirudin 250 mg injection The Medicines Company Yes Budesonide (Nasocort) nasal spray AstraZeneca Yes Bupivacaine liposome injection (Exparel) Pacira No Glycerol is of animal origin (could not specify bovine or porcine) Bupivacaine 0.25% injection Hospira Yes Bupivacaine 0.5% injection Hospira Yes Bupivacaine 0.0625% - hydromorphone 10mcg/ml epidural DCF Yes Bupivacaine 0.125% - Hydromorphone 10mcg/ml epidural DCF Yes Bupivacaine 0.125% - Hydromorphone 10mcg/ml - clonidine 1mcg/ml epidural DCF Yes Bupivacaine 0.125% - Hydromorphone 25mcg/ml epidural DCF Yes Bupivacaine 0.25% - Hydromorphone 10mcg/ml epidural DCF Yes Calcium chloride 100 mg/mL injection DCF Yes Carbidopa-levodopa 25mg-100mg tablet McKesson No Contains magnesium stearate Carbidopa-levodopa 25mg-100mg ER tablet Mylan No Contains magnesium stearate Carisoprodol 350mg tablet American Health No Cefazolin injection Sandoz Yes No excipients added to cefazolin products Cefazolin 1 gm injection Hikma (Westward) Yes No animal byproducts Cefazolin 2 gm injection B Braun Yes Cefuroxime injection West-Ward Yes Cefuroxime 1.5 gm injection Sagent Yes Per manufacturer: No animal products are used in production Celecoxib 100 mg, 200 mg capsule Mylan, Major No Contains gelatin (bovine and porcine) Chlorhexidine (Peridex) 3M ESPE Yes Ciprofloxacin injection Claris Yes No animal byproducts or gluten. No final product testing for either. Cisatracurium injection Fresenius Kabi/Sandoz Yes Clevidipine 0.5 mg/mL injection Fresenius Kabi Yes Glycerin is plant-derived per manufacturer. No final product testing done Clindamycin injection Hospira Unknown Product divested Clonazepam tablet Mckesson No Clonidine 100 mcg/mL injection X-Gen Yes Clonidine 0.1mg tablet Mylan No Cyclobenzaprine tablet McKesson, Major, Mylan No Cyclosporine 25mg, 100mg capsule Novartis No Contains gelatin Cystografin Bracco Yes No animal byproducts or gluten. No final product testing for either. Desflurane Baxter Yes Dexamethasone injection Fresenius Kabi Yes No animal byproducts or gluten. No final product testing for either. Dexmedetomidine 4 mcg/mL injection Hospira Yes Dextrose 50% in water 12.5g DCF & Hospira Yes Diazepam 5 mg, 10 mg tablet McKesson, Mylan No Diazepam 1mg/ml 5ml soln Precision Dose Yes Diazepam 5mg/ml 2ml tubex IV Hospira Yes Diphenhydramine injection Fresenius Yes No animal byproducts or gluten. No final product testing for either. Diphenhydramine tablet Contract Pharm & Major No Need specific lot number; ingredient sources lot-specific (Lactose, Mg stearate, gelatin listed) Duke Eye Mix (Adult #2) DCF Yes Duke Eye Mix (Pediatric) DCF Yes Electrolyte-A (Plasma-Lyte A) Yes Ephedrine 50 mg IV Par Yes Epinephrine inj. 1:1,000 PF BPI Labs Yes Epinephrine drip JHP Yes Ertapenem 1 gm injection Merck Yes No ruminant animals (e.g. cows) products are used in manufacturing; no final testing for alpha-gal Esomeprazole oral suspension AstraZeneca Yes Ezetimibe 10 mg tablet Sun Pharma, Avkare No Famotidine 10 mg/mL injection Fresenius Kabi Yes Fentanyl injection Hospira, Akorn, DCF Yes Fentanyl PCA syringe DCF Yes Fentanyl patch (all strengths) Mylan Yes Floseal hemostatic matrix Baxter No Bovine gelatin Furosemide 20 mg tablet Sandoz No Furosemide 10 mg/mL oral solution West-Ward Yes Gabapentin capsule (all strengths) Amneal & McKesson No Contains gelatin (bovine and porcine) Gabapentin capsule (all strengths) AvKARE No Contains gelatin (bovine, porcine) & gluten (not gliaden gluten - type responsible for celiac sprue) Gabapentin capsule (all strengths) Mylan & American Health No Contains gelatin (bovine and porcine) Gabapentin capsule (all strengths) Ascend No Gelatin - bovine Gabapentin capsule (all strengths) Pfizer No Gelatin Gabapentin (Neurontin) 250 mg/5 mL oral solution Pfizer No Gabapentin 250 mg/5 mL oral solution Amneal Yes Gabapentin 250 mg/5 mL oral solution Greenstone No Animal source gelatin Gelflim 25 mm-50 mm/125 mm-100 mm Pfizer No Contains porcine gelatin Gentamicin injection Baxter, Fresenius Kabi Yes Glucagon injection Bedford No Contains lactose monohydrate (may be animal derived) Glycopyrrolate West-Ward yes Haloperidol 5 mg/mL injection Fresenius Kabi No Lactic Acid may be animal derived Heparin All (porcine) No Porcine derived Hydralazine 20 mg/mL injection Frasenius Kabi Yes Magnesium stearate; typically gluten-free, but due to sourcing there may be cross-contamination. Final testing is Hydrocodone-acetaminophen tablet Mallinckrodt No done for this. Hydrocortisone 100 mg injection Pharmacia & Upjohn (Pfizer) Yes No animal byproducts listed or used in manufacture Hydromorphone injection Hospira No Lactic Acid may be animal derived Hydromorphone 1 mg/mL injection (pre-filled syringe) Fresenius Kabi Yes Hydromorphone 1 mg/mL injection (Compounded) DCF Yes Hydromorphone 2mg, 4mg tablet Westward, Rhodes No Hydromorphone ER tablet Paddock No Hydromorphone 10mcg/ml Epidural DCF Yes Hydromorphone 25mcg/ml Epidural DCF Yes Hydromorphone PCA syringe DCF Yes Ibuprofen tablet (all strengths) LNK; Major & McKesson No Contains lactose (bovine) Ibuprofen 100 mg/5 mL suspension Precision Dose No Contains glycerin IC Green Akorn Yes No animal byproducts or gluten. No final testing for either. Imitrex 100 mg tablet GSK No Magnesium stearate - animal derived Imitrex 20 mg nasal spray GSK Yes Imitrex 4 mg, 6 mg injection GSK Yes Influenza vaccine (Fluzone High Dose) Sanofi Yes Influenza vaccine (Flulaval) GSK No Sodium deoxycholate may of animal origin - ovine or bovine Influenza vaccine (Flublok) Sanofi Yes No animal byproducts Instat Microfibrillar Collagen Hemostat Ethicon No Contains bovine collagen Insulin glargine (Lantus) Sanofi Yes Insulin human Lilly (Humulin R) Yes Per manufacturer: Glycerin is product is plant derived Isoflurane Baxter Yes Isosorbide Dinitrate 5 mg tablet Sandoz No Isovue M-200 Bracco Yes No animal byproducts or gluten. No final product testing for either. Ketamine injection Par, Mylan, Hospira Yes Labetolol 100mg/20ml injection Hospira/Akorn Yes Labetolol 5 mg/mL injection (Carpuject) Hospira Yes Lacosamide injection (all strengths) UCB Yes Lacosamide 10 mg/mL oral solution UCB No Contains glycerin Lacosamide tablet (all strengths) UCB No Levetiracetam 500 mg/5 mL injection Sagent Yes No animal byproducts used in manufacture Levetiracetam tablet American Health No Contains
Recommended publications
  • Magnesium Stearate
    SAFETY DATA SHEET Magnesium Stearate SECTION 1 - PRODUCT AND COMPANY IDENTIFICATION 1.1 Product identifier Product Name: Magnesium Stearate Product Code(s): Magnesium Stearate Synonym(s): Octadecanoic acid, magnesium salt; Dibasic magnesium stearate; Stearic acid, magnesium salt REACH Registration Number: No data available 1.2 Relevant identified uses of the substance or mixture and uses advised against General use: For use in industrial and laboratory applications Uses advised against: None known 1.3 Details of the supplier and of the safety data sheet Manufacturer/Distributor Allan Chemical Corporation 235 Margaret King Avenue Ringwood, NJ 07456 USA +1-973-962-4014 1.4 Emergency telephone number Chem Tel +1-813-248-0585 +1-800-255-3924 SECTION 2 - HAZARDS IDENTIFICATION 2.1 Classification of substance or mixture Product definition: Substance Classification in accordance with 29 CFR 1910 (OSHA HCS) and Regulation EC No. 1272/2008 Not a dangerous substance according to OSHA or to European Union Legislation 2.2 Label Elements Not classified as dangerous according to GHS 2.3 Hazards not otherwise classified (HNOC) or not covered by GHS May form combustible dust concentrations in air SECTION 3 - COMPOSITION/INFORMATION ON INGREDIENTS 3.1 Substances % by Weight Ingredient CAS Number EC Number Index Number GHS Classification >99 Magnesium Stearate 557-04-0 209-150-3 ------------ ------------ There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence, require reporting in this section. 3.2 Mixtures Not applicable SECTION 4 - FIRST AID MEASURES 4.1 Description of first aid measures Inhalation: If exposure to product mist causes respiratory irritation or distress, move the exposed person to fresh air immediately.
    [Show full text]
  • Calcium Stearate Processing
    National Organic Standards Board Technical Advisory Panel (TAP) Review Compiled by University of California Sustainable Agriculture Research and Education Program (UC SAREP) for the USDA National Organic Program Calcium Stearate Processing Executive Summary1 A petition is under consideration with respect to NOP regulations subpart G §205.605, governing the use of substances in processed products: Petitioned: Inclusion of calcium stearate on National List of nonagricultural substances allowed in or on processed products labeled as “organic” or “made with organic (specified ingredients or food group(s)).” Calcium stearate is a compound of calcium with a mixture of solid organic acids obtained from edible sources. It is generally used as a solid-phase lubricant that reduces friction between particles of the substance to which it is added. The Petitioner’s intended use is “as a flow agent (anti-dusting agent)” to be used in dry flour based ingredients sold to bakeries (NOSB Petition). The NOP has no prior listing or ruling on the substance. All three reviewers agreed that the substance should be considered synthetic. The reviewers were divided over the use of calcium stearate in food labeled as “organic.” Two of the reviewers felt it should not be allowed in these foods, while one reviewer felt it should be accepted. One reviewer who voted to restrict its use indicated that more information was needed on the nature of the substance and its potential applications, and the other reviewer felt that inclusion of a “synthetic” substance in organics runs contrary to consumer’s expectations regarding organic products. All three reviewers agreed that the substance should be allowed in products labeled as “made with organic…” ingredients.
    [Show full text]
  • Learner Notification International Society for Heart & Lung
    Learner Notification International Society for Heart & Lung Transplantation (ISHLT) 41st Annual Meeting & Scientific Sessions Virtual Experience April 24 – 28, 2021 Live Virtual Acknowledgement of Financial Commercial Support Abbott Medtronic United Therapeutics Acknowledgement of In-Kind Commercial Support No in-kind commercial support was received for this educational activity. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety as partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Physicians (ACCME) The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement - ISHLT designates this live virtual activity for a maximum of 32.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISHLT. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Nurses (ANCC) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 ANCC contact hours. Pharmacists (ACPE) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 knowledge-based CPE contact hours.
    [Show full text]
  • Resource #350932
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− September 2019 ~ Resource #350932 Anticipated Availability of First-Time Generics ―To help explain the benefits of generic drugs to your patients, the FDA has patient education materials available at https://www.fda.gov/drugs/generic-drugs/patient-education ― Branda Generic Name Generic Manufacturer(s)b,1 Anticipated Availabilityc (Manufacturer) Acanya Benzoyl peroxide 2.5%/ Teva Generic now available (Valeant) Clindamycin phosphate 1.2% Cuprimine Penicillamine capsule Amerigen, Teva Generic now available (Bausch Health) Delzicol Mesalamine delayed-release Teva Generic now available (Warner Chilcott) capsule Diclegis Doxylamine/Pyridoxine Teva Generic now available (Duchesnay) Exjade Deferasirox tablets for oral Teva Generic now available (Novartis) suspension Fareston Toremifene Rising (EirGen Pharma Limited) Generic now available (Kyowa Kirin) Faslodex Fulvestrant Sandoz Generic now available (AstraZeneca) Firazyr Icatibant Teva Generic now available (Shire Orphan Therapies) Gablofen Baclofen 1 mg/mL single dose Mylan Institutional Generic now available (Piramal) vial Hemabate Carboprost tromethamine Dr. Reddy’s Generic now available (Pharmacia & Upjohn) Letairis Ambrisentan Cipla, Mylan, Par, Sigmapharm, Sun, Teva, Generic now available (Gilead) Zydus Lexiva Fosamprenavir Mylan Generic now available (Viv) More. Copyright © 2019 by Therapeutic Research Center 3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249 pharmacist.therapeuticresearch.com ~ prescriber.therapeuticresearch.com ~ pharmacytech.therapeuticresearch.com ~ nursesletter.therapeuticresearch.com (Clinical Resource #350932: Page 2 of 24) Branda Generic Name Generic Manufacturer(s)b,1 Anticipated Availabilityc (Manufacturer) Lotemax Loteprednol ophthalmic Hi-tech Generic now available (Bausch & Lomb) suspension Lyrica Pregabalin capsule Alembic, Amneal, Ascend (Alkem), Cipla Generic now available (PF Prism CV) (InvaGen), Dr.
    [Show full text]
  • Gilead Sciences, Inc. November 13, 2016
    Student Investment Management Gilead Sciences, Inc. November 13, 2016 Gilead Sciences, Inc. NASDAQ: GILD BUY $92.00 The Fisher College of Business Student Investment Management Program is initiating coverage on Gilead Sciences with a BUY rating. Our target price is $92.00. Our implied P/E for 2016E is 7.9x versus consensus 6.5x. Our 2017 and 2018 estimates are 8.8x and 9.5x, respectively. Company overview Gilead Sciences, Inc. is a research-based biopharmaceutical Fund Manager company that discovers, develops and commercializes innovative Royce West, CFA medicines in areas of unmet medical need. Gilead strives to 614-227-2948 transform and simplify care for people with life-threatening illnesses [email protected] around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver Analyst diseases, cancer, inflammatory and respiratory diseases, and Andrew Jasen cardiovascular conditions. 301-300-0702 [email protected] 12-Month trading performance 10.0% S&P Current share price: $72.64 7.0% 52 wk range: $71.76 - $108.13 0.0% S5HLTH Market cap: $99.9bn 1.4% P/E: 6.8x (10.0%) XBI (3.0%) Diluted shares out.: 1.3bn Last dividend (9/4/2016): $0.47 (20.0%) GILD Dividend yield: 2.4% (25.5%) Beta: 0.94 (30.0%) EV/EBITDA: 4.8x EV/Sales: 3.1x (40.0%) Nov-15 Jan-16 Mar-16 May-16 Jul-16 Sep-16 Nov-16 Investment thesis We are placing a BUY rating on GILD with a price target of $92.00, a 20.4% upside to the current trading price.
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Amgen-Opinion-Jan-7-2021.Pdf
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELA WARE AMGEN INC. and AMGEN MANUFACTURING, LIMITED, Plaintiffs, v. Civil Action No. 20-0561-CFC HOSPIRA, INC. and PFIZER INC. Defendants. MEMORANDUM ORDER Having considered the merits of Defendants Hospira, Inc. and Pfizer Inc.' s Motion to Stay (D.I. 19) and the briefs filed by the parties in connection with that motion, it is HEREBY ORDERED that Defendants' motion to stay is GRANTED IN PART for the following reasons: 1. Plaintiffs Amgen Inc. and Amgen Manufacturing, Limited make and sell the biologic filgrastim under the brand name Neupogen®. Filgrastim, like many biologics, is a protein. Plaintiffs own two patents generally related to methods of purifying such proteins. These two patents are U.S. Patent Nos. 10,577,392 (the #392 patent), and 9,643,997 (the #997 patent). The #392 patent issued in March of 2020. 2. Defendants manufacture and sell a biosimilar version Neupogen® called Nivestym®. Nivestym® has been available since 2018 and is the third biosimilar version ofNeupogen® launched in the United States since Neupogen® became available almost thirty years ago. 3. Both the #392 patent and #997 patent have been asserted against the Defendants-albeit in different actions-for the manufacture ofNivestym®. The #392 patent has been asserted in this case (C.A. 20-0561 ), which was filed on April 24, 2020. The #997 patent has been asserted in the related case Amgen Inc. et al. v. Hospira, Inc. et al., No. 18-cv-1064-CFC-CJB (D. Del. 2018). That case is scheduled for a jury trial to begin on May 17, 2021.
    [Show full text]
  • Magnesium Stearate
    United States Department of Agriculture Agricultural Marketing Service | National Organic Program Document Cover Sheet https://www.ams.usda.gov/rules-regulations/organic/national-list/petitioned Document Type: ☐ National List Petition or Petition Update A petition is a request to amend the USDA National Organic Program’s National List of Allowed and Prohibited Substances (National List). Any person may submit a petition to have a substance evaluated by the National Organic Standards Board (7 CFR 205.607(a)). Guidelines for submitting a petition are available in the NOP Handbook as NOP 3011, National List Petition Guidelines. Petitions are posted for the public on the NOP website for Petitioned Substances. ☒ Technical Report A technical report is developed in response to a petition to amend the National List. Reports are also developed to assist in the review of substances that are already on the National List. Technical reports are completed by third-party contractors and are available to the public on the NOP website for Petitioned Substances. Contractor names and dates completed are available in the report. Magnesium Stearate Handling/Processing 1 2 Identification of Petitioned Substance 13 3 Chemical Names: 14 Trade Names: 4 Magnesium stearate 15 N/A 5 Octadecanoic acid magnesium salt 6 Magnesium octadecanoate CAS Numbers: 7 557-04-0 8 Other Name: 9 Stearic acid magnesium salt 10 Magnesium distearate Other Codes: 11 EC-No. 209-150-3 12 INS No. 470(iii) 16 17 Summary of Petitioned Use 18 Magnesium stearate is used as a lubricant or anticaking agent in food processing and handling. Magnesium 19 stearate is currently listed on the National List of Allowed and Prohibited Substances as a synthetic 20 nonagricultural (nonorganic) substance allowed as ingredients in or on processed products labeled as “organic” 21 or “made with organic (specified ingredients or food group(s))” (7 Code of Federal Regulation (CFR) 205.605(b)).
    [Show full text]
  • Pharmaceutical Compositions of Rifaximin Pharmazeutische Rifaximin-Zusammensetzungen Compositions Pharmaceutiques De Rifaximine
    (19) TZZ Z__ T (11) EP 2 011 486 B2 (12) NEW EUROPEAN PATENT SPECIFICATION After opposition procedure (45) Date of publication and mention (51) Int Cl.: of the opposition decision: A61K 9/20 (2006.01) A61K 31/44 (2006.01) 12.08.2015 Bulletin 2015/33 (45) Mention of the grant of the patent: 23.05.2012 Bulletin 2012/21 (21) Application number: 08252198.0 (22) Date of filing: 26.06.2008 (54) Pharmaceutical compositions of rifaximin Pharmazeutische Rifaximin-Zusammensetzungen Compositions pharmaceutiques de rifaximine (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR EP-A1- 0 616 808 EP-B1- 1 763 339 HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT WO-A-2006/094737 WO-A2-2006/039022 RO SE SI SK TR US-A- 6 140 355 US-A1- 2005 101 598 (30) Priority: 06.07.2007 IN KO09682007 • DUPONT ET AL: "Treatment of Travelers’ 23.06.2008 EP 08252158 Diarrhea: Randomized Trial Comparing Rifaximin, Rifaximin Plus Loperamide, and (43) Date of publication of application: Loperamide Alone" CLINICAL 07.01.2009 Bulletin 2009/02 GASTROENTEROLOGY AND HEPATOLOGY, AMERICAN GASTROENTEROLOGICAL (60) Divisional application: ASSOCIATION, US, vol. 5, no. 4, 17 April 2007 11176043.5 / 2 420 226 (2007-04-17), pages 451-456, XP022029177 ISSN: 14186563.4 / 2 837 378 1542-3565 • ARYA ET AL: "Rifaximin-the promising anti- (73) Proprietor: Lupin Ltd. microbial for enteric infections" JOURNAL OF Mumbai, Maharashtra 400 098 (IN) INFECTION, ACADEMIC PRESS, LONDON, GB, vol.
    [Show full text]
  • In the Supreme Court of the United States   ACORDA THERAPEUTICS, INC., Petitioner
    NO. 181280 In the Supreme Court of the United States ACORDA THERAPEUTICS, INC., Petitioner, v. ROXANE LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., and TEVA PHARMACEUTICALS USA, INC., Respondents. On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit BRIEF OF AMICUS CURIAE BOSTON PATENT LAW ASSOCIATION IN SUPPORT OF NEITHER PARTY SOPHIE F. WANG COUNSEL OF RECORD BRYANA T. MCGILLYCUDDY NATALIA SMYCHKOVICH CHOATE HALL & STEWART LLP TWO INTERNATIONAL PLACE BOSTON, MA 02110 (617) 248-5000 [email protected] MAY 8, 2019 COUNSEL FOR AMICUS CURIAE SUPREME COURT PRESS ʕ (888) 958-5705 ʕ BOSTON, MASSACHUSETTS i TABLE OF CONTENTS Page TABLE OF AUTHORITIES ....................................... ii INTEREST OF THE AMICUS CURIAE ................... 1 SUMMARY OF ARGUMENT .................................... 1 ARGUMENT ............................................................... 3 I. THE FEDERAL CIRCUIT’S DECISION CREATES SIGNIFICANT UNCERTAINTY CONCERNING THE SCOPE AND APPLICABILITY OF THE BLOCKING PATENT DOCTRINE. ............................................ 3 A. Clarification Is Needed as to the Definition of a “Blocking Patent.” .............. 3 B. Clarification Is Also Needed as to Whether and How the Blocking Patent Doctrine Should Be Applied to Objective Indicia of NonObviousness. ...................... 8 II. ABSENT CLARIFICATION, THE EXPANDED BLOCKING PATENT DOCTRINE HAS A CHILLING EFFECT ON INNOVATION AND INVESTMENT. .................. 11 A. Improvement Innovations Are Critical and Require Significant Investment. ....... 11 B. Objective Indicia Matter. .......................... 13 CONCLUSION .......................................................... 16 ii TABLE OF AUTHORITIES TABLE OF AUTHORITIES Page CASES Acorda Therapeutics, Inc. v. Roxane Labs., Inc., 903 F.3d 1310 (Fed. Cir. 2018) ......... passim Apple v. ITC, 725 F.3d 1356 (Fed. Cir. 2013) ......................... 14 Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990) ............................................. 6 Galderma Labs., L.P.
    [Show full text]
  • Lubricants in Pharmaceutical Solid Dosage Forms
    Lubricants 2014, 2, 21-43; doi:10.3390/lubricants2010021 OPEN ACCESS lubricants ISSN 2075-4442 www.mdpi.com/journal/lubricants Review Lubricants in Pharmaceutical Solid Dosage Forms Jinjiang Li * and Yongmei Wu Drug Product Science & Technology, Bristol-Myers Squibb Corporation, 1 Squibb Dr., New Brunswick, NJ 08903, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-732-227-6584; Fax: +1-732-227-3784. Received: 18 December 2013; in revised form: 21 January 2014 / Accepted: 24 January 2014 / Published: 25 February 2014 Abstract: Lubrication plays a key role in successful manufacturing of pharmaceutical solid dosage forms; lubricants are essential ingredients in robust formulations to achieve this. Although many failures in pharmaceutical manufacturing operations are caused by issues related to lubrication, in general, lubricants do not gain adequate attention in the development of pharmaceutical formulations. In this paper, the fundamental background on lubrication is introduced, in which the relationships between lubrication and friction/adhesion forces are discussed. Then, the application of lubrication in the development of pharmaceutical products and manufacturing processes is discussed with an emphasis on magnesium stearate. In particular, the effect of its hydration state (anhydrate, monohydrate, dihydrate, and trihydrate) and its powder characteristics on lubrication efficiency, as well as product and process performance is summarized. In addition, the impact of lubrication on the dynamics of compaction/compression processes and on the mechanical properties of compacts/tablets is presented. Furthermore, the online monitoring of magnesium stearate in a blending process is briefly mentioned. Finally, the chemical compatibility of active pharmaceutical ingredient (API) with magnesium stearate and its reactive impurities is reviewed with examples from the literature illustrating the various reaction mechanisms involved.
    [Show full text]
  • [J-52A-2014] in the Supreme Court of Pennsylvania Middle District
    [J-52A-2014] IN THE SUPREME COURT OF PENNSYLVANIA MIDDLE DISTRICT COMMONWEALTH OF PENNSYLVANIA : 84 MAP 2011 : : Appeal from the decision of the : Commonwealth Court (Opinion re Post- v. : Trial Motions of the Commonwealth and : Johnson & Johnson) dated 8/31/11 at No. : 212 MD 2004 TAP PHARMACEUTICAL PRODUCTS, : INC.; ABBOTT LABORATORIES; : ASTRAZENECA PLC; ASTRAZENECA, : HOLDINGS, INC.; ASTRAZENECA : PHARMACEUTICALS LP; : ASTRAZENECA LP; BAYER AG; BAYER : CORPORATION; SMITHKLINE : BEECHAM CORPORATION D/B/A : GLAXOSMITHKLINE; PFIZER, INC.; : PHARMACIA CORPORATION; : JOHNSON & JOHNSON; ALZA : CORPORATION; CENTROCOR, INC.; : ETHICON, INC.; JANSSEN : PHARMACEUTICAL PRODUCTS, L.P.; : MCNEIL-PPC, INC.; ORTHO BIOTECH, : INC.; ORTHO BIOTECH PRODUCTS; : L.P.; ORTHO-MCNEIL : PHARMACEUTICAL, INC.; AMGEN INC.; : IMMUNEX CORPORATION; BRISTOL- : MYERS SQUIBB COMPANY; BAXTER : INTERNATIONAL INC.; BAXTER : HEALTHCARE CORPORATION; : IMMUNO-U.S., INC.; AVENTIS : PHARMACEUTICALS, INC.; AVENTIS : BEHRING, L.L.C.; HOECHST MARION : ROUSSEL, INC., BOEHRINGER : INGELHEIM CORPORATION; : BOEHRINGER INGELHEIM : PHARMACEUTICALS, INC.; BEN VENUE : LABORATORIES; BEDFORD : LABORATORIES; ROXANE : LABORATORIES; SCHERING-PLOUGH : CORPORATION; WARRICK : PHARMACEUTICALS CORPORATION; : SCHERING SALES CORPORATION; : DEY, INC. : : DONNA A. BOSWELL, ESQ., ANN M. : VICKERY, ESQ., AND JOSEPH A. : YOUNG, ESQ., : Intervenors : : APPEAL OF: JOHNSON & JOHNSON, : ALZA CORPORATION, CENTOCOR, : INC., ETHICON, INC., JANSSEN : PHARMACEUTICAL PRODUCTS, L.P., : MCNEIL-PPC, INC., ORTHO BIOTECH, : INC., ORTHO BIOTECH PRODUCTS, : L.P., AND ORTHO-MCNEIL : PHARMACEUTICAL, INC. : (COLLECTIVELY, THE “JOHNSON & : JOHNSON DEFENDANTS”) : ORDER PER CURIAM DECIDED: June 16, 2014 AND NOW, this 16th day of June, 2014, the Order of the Commonwealth Court is VACATED, and the matter is remanded per the terms of Mr. Justice Baer’s responsive opinion in Commonwealth v. TAP Pharm. Prods., Inc., J-52B-2014, ___ A.3d ___ (Pa.
    [Show full text]